toripalimab,cisplatin,temozolomide
junshi biosciences,coherus
['cisplatin', 'toripalimab', 'melanoma', 'temozolomide']
adjuvant chemotherapy (temozolomide plus cisplatin) shows remarkable longer rfs, dmfs, and os than toripalimab (anti-pd-1). it suggested that adjuvant chemotherapy may be a better option for patients with resected mucosal melanoma even in the present immunotherapy era. #asco23 
Biomedical Science that Inspires. #medicine #medtwitter #meded #Science #Research #Technology #News